We discuss a novel strategy using RNA anti sense technology for treating geographic atrophy with Dr. Nik London,  San Diego, California.

We discuss the 18 month results of the Derby and Oaks trials of pegcetacoplan for treatment of geographic atrophy with Roger Goldberg, MD of Walnut Creek, California.

We discuss a new retinal sealant that may replace the need for tamponade with expansile gas or silicone oil with Dr. James Anthony Stefater.

We discuss how new developments in imaging and therapeutics have impacted the treatment of sickle cell retinopathy with Dr. Adrienne Scott, Professor of Ophthalmology at Johns Hopkins and the Wilmer Eye Institute.

We discuss the results of a Phase II clinical trail studying the efficacy of high dose aflibercept (8mg) for treating neovascular AMD with Dr. David Brown of Retina Consultants of Texas in Houston.

We discuss new developments in the diagnosis and therapy of choroidal melanoma with Dr. Paul Finger, Clinical Professor, NYU and Chair, Eye Cancer Foundation.

We discuss the two year results of a Phase I/II trial of a stem cell  implant for the treatment of geographic atrophy with Dr. Amir Kashani, Associate Professor, Wilmer Eye Institute.

We discuss the one year results of the DERBY and OAKs studies treating geographic atrophy with Dr. David Lally,  Assistant Professor University of Massachusetts and Tufts University.

We discuss the use of deep learning techniques in the detection and management of macular degeneration with Dr. Pearse Keane, Consultant Moorfields Eye Hospital, Professor of Artificial Medical Intelligence University College London.

In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.